scholarly journals CLINICAL VALUE OF BIOCHEMICAL MARKERS OF NEUROENDOCRINE TUMORS

2019 ◽  
Vol 19 (1S) ◽  
pp. 28-29
Author(s):  
N V Lyubimova ◽  
Yu S Timofeev ◽  
M G Toms ◽  
T Yu Kharitidi ◽  
O I Vashketova ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Biochemical Markers ◽  
Chromogranin A ◽  
Endocrine System ◽  
Progression Free Survival ◽  
High Sensitivity ◽  
Biologically Active ◽  
Clinical Value ◽  
Diagnostic Significance

Neuroendocrine tumors (NET) is a heterogeneous group of epithelial neoplasms that develop from cells of the diffuse endocrine system and found in any organ. A distinctive feature of NET is the ability to produce various biologically active peptides and amines. Currently, the most useful markers are the universal marker chromogranin-A (CgA) and specific markers serotonin and 5-hydroxyindolylacetic acid (5-HIAA). The analysis of the clinical significance of the biochemical markers of NETs was carried out by comparative analysis of their levels in serum and urine of 339 NET patients and 66 healthy people. Determination of plasma CgA, serotonin in serum and 5-HIAA in daily urine was performed using standardized ELISA methods using the Chromogranin A ELISA kit (Dako), Serotonin ELISA and 5-HIAA ELISA (IBL) test-systems. The values of CgA, serotonin, 5-HIAA in patients with NET were significantly (p < 0.001) higher than the corresponding control values. Assessment of the diagnostic significance of CgA, taking into account the cut-off level 33 U/l (with a specificity of 98.5%), showed high sensitivity in the general NET group - 80.9%. The serial determination of the marker reflected the effect of treatment. The progression free survival in different treatment regimens for patients with NET has been associated with basal levels of CgA. The medians of serotonin and 5-HIAA levels were maximal in patients with carcinoid syndrome, significantly exceeding the corresponding values in NET patients without clinical manifestations.The data indicate the possibility of using CgA, serotonin and 5-HIAA to improve the accuracy of diagnosis, evaluation of generalization and biological activity of NETs.

Chromogranin a Measurement in Neuroendocrine Tumors

1998 ◽  
Vol 13 (1) ◽  
pp. 3-9 ◽  
Author(s):  
L. Ferrari ◽  
E. Seregni ◽  
A. Martinetti ◽  
B Van Graafeiland ◽  
S. Nerini-Molteni ◽  
...  
Keyword(s):  
Tumor Marker ◽  
Neuroendocrine Tumors ◽  
Chromogranin A ◽  
High Sensitivity ◽  
Biologically Active ◽  
Proliferative Index ◽  
Favorable Prognosis ◽  
Blood Marker ◽  
Active Substances

Neuroendocrine tumors (NETs) are rare neoplasms characterized by a low proliferative index and, in some cases, a favorable prognosis. These tumors often overproduce and release biologically active substances that are responsible for severe syndromes. Tumor marker measurement provides the clinician with useful information for the management of NET patients. The substances released by overproducing tumors are currently used as biomarkers, but there is a need for sensitive markers also for the “biochemically silent” NETs. The most effective and reliable blood marker available today is chromogranin A (CgA). Because of its high sensitivity and specificity, this glycoprotein can be used for the diagnosis, prognosis and follow-up of NETs. Furthermore, CgA measurement can be used for monitoring those tumors not overproducing or releasing any hormones or biological amines. This paper is a synthetic review on the value of CgA in NET management and reports our experiences with CgA measurement in NET patients.

scholarly journals Chromogranin A and chromogranin B in pancreatic neuroendocrine tumors

2020 ◽  
pp. 26-28
Author(s):  
N. V. Lyubimova ◽  
Yu. S. Timofeev ◽  
A. V. Lebedeva ◽  
N. E. Kushlinsky
Keyword(s):  
Blood Serum ◽  
Neuroendocrine Tumors ◽  
Chromogranin A ◽  
Diagnostic Sensitivity ◽  
Control Group ◽  
Pancreatic Neuroendocrine Tumors ◽  
Chromogranin B ◽  
Tumor Dissemination ◽  
First Time

For the first time in Russia a comparative study of chromogranin A (CgA) and chromogranin B (CgB) in neuroendocrine tumors (NETs) of the pancreas was performed. We examined 50 primary patients with pancreatic NETs and 42 healthy people. The determination of CgA and CgB was performed in blood serum using standard enzyme-linked immunoassay test-systems (Chromogranin A NEOLISA, Eurodiagnostica; Human Chromogranin B, USCN). The levels of CgA and CgB in pancreatic NETs significantly differed from the control group. There was found the association between CgA levels and the dissemination of the process, while CgB demonstrated the properties of a marker independent from the tumor dissemination. The diagnostic sensitivity of CgA was 76 %, CgB – 68 %. Complex determination of CgA and CgB enhanced the diagnostic sensitivity to 84 %. Our data indicate the potential usefulness of complex CgA and CgB in the diagnosis of pancreatic NETs.

scholarly journals Significance of Chromogranin A in Diagnosis and Prognosis of Neuroendocrine Tumors

2019 ◽  
Vol 2 (17) ◽  
pp. 19-22 ◽  
Author(s):  
N. V. Lyubimova ◽  
Yu. S. Timofeev ◽  
T. K. Churikova ◽  
A. E. Kuzminov ◽  
N. E. Kushlinsky
Keyword(s):  
Neuroendocrine Tumors ◽  
Chromogranin A ◽  
High Efficiency ◽  
Prognostic Significance ◽  
Progression Free Survival ◽  
Healthy Individuals ◽  
Free Survival ◽  
Diagnosis And Prognosis ◽  
Different Types ◽  
The Comparative Study

We present the comparative study of plasma chromogranin A (CgA) levels measured in 232 patients with different types of neuroendocrine tumors (NETs) and 66 healthy individuals using enzyme immunoassay Chromogranin A ELISA kit (Dako). CgA levels were significantly higher in patients with all types of NETs than in healthy subjects. CgA secretion were highly variable. The study demonstrate high diagnostic sensitivity of CgA, which was 80.6 % in overall group of NETs with specificity 98.5 %. We confirmed the prognostic significance of CgA, in this case the high basal levels of CgA (above 100 U/l) were significantly associated with less favorable prognosis of progression free survival after different types of treatment. The data confirms high efficiency of CgA as biomarker, which measurement enhances the accuracy of diagnosis and prognosis of NETs.

The value of copeptin in the diagnosis and prognosis of cardiovascular diseases

2020 ◽  
Vol 98 (3) ◽  
pp. 203-209
Author(s):  
A. M. Aliyevа ◽  
I. I. Almazova ◽  
T. V. Pinchuk ◽  
E. V. Resnick ◽  
Yu. N. Fedulaev ◽  
...  
Keyword(s):  
High Sensitivity ◽  
Special Role ◽  
Clinical Value ◽  
Diagnosis And Prognosis ◽  
Patients With Heart Failure ◽  
Risk Patients ◽  
Coronary Syndromes ◽  
Very High ◽  
Important Marker

Vasopressin and its receptors play a key role in maintaining homeostasis in physiological and pathophysiological conditions. As a result, the vasopressin system has become an important target for both diagnostic and therapeutic use in a number of diseases. Kopeptin, C-terminal part of vasopressin prohormone. Copeptin has come to be seen as an important marker for identifying high-risk patients and predicting outcomes for various diseases. This improves the clinical value of commonly used biomarkers and risk stratification tools. The area that could benefit most from the introduction of the copeptin measurement in practice is cardiovascular disease. Determination of the level of copeptin becomes a fast and reliable method of differential diagnosis, especially in acute coronary syndromes. A special role in the diagnosis of acute myocardial infarction (AMI) is given to the combination of copeptin and troponin. According to available sources, such a combination eliminates AMI with very high sensitivity and negative predictive value. Moreover, elevated levels of copeptin correlate with poorer prognosis, and a higher risk of side effects after AMI, especially in patients with heart failure.

Comparison between Two Methods in the Determination of Circulating Chromogranin A in Neuroendocrine Tumors (NETs): Results of a Prospective Multicenter Observational Study

2005 ◽  
Vol 20 (3) ◽  
pp. 156-168 ◽  
Author(s):  
A. Leon ◽  
M. Torta ◽  
R. Dittadi ◽  
E. degli Uberti ◽  
M.R. Ambrosio ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Diagnostic Performance ◽  
Polyclonal Antibodies ◽  
Clinical Samples ◽  
Enzyme Linked Immunosorbent Assay ◽  
Clinical Value ◽  
Multicenter Observational Study ◽  
Prospective Multicenter Observational Study ◽  
Local Laboratory

Several methods for analyzing CgA using either monoclonal or polyclonal antibodies have been developed, which differ in their diagnostic performance. The present paper describes the results of a prospective multicenter study aimed at comparing the clinical value of the two most widely used commercially available CgA assay kits in patients affected by neuroendocrine tumors (NETs). Two hundred sixty-one patients from 40 different centers and 99 healthy subjects were evaluated. CgA levels were measured with two different methods, a two-step immunoradiometric assay (IRMA) and an enzyme-linked immunosorbent assay (ELISA). CgA was measured centrally by two reference laboratories, one of which used IRMA and the other ELISA, and it was measured by the participating institutions with the method routinely used by each of them. The major findings of the present study were: (i) the two assays for the determination of CgA present good diagnostic performance; (ii) both assays are robust and guarantee comparable results when applied in different settings (central vs local laboratory); (iii) the negative/positive cutoff points (87 ng/mL for IRMA and 21.3 U/L for ELISA) were established according to standardized criteria; (iv) the results obtained with the two assays in basal clinical samples of patients affected by NETs show an apparently satisfactory correlation (rs=0.843, p<0.0001). However, a possibly clinically meaningful 36% discordance rate was found. These findings support the hypothesis that the two CgA kits might provide partially different information.

Standard Pre- and Postoperative Determination of Chromogranin A in Resectable Non-Functioning Pancreatic Neuroendocrine Tumors - Diagnostic Accuracy: NF-pNET and Low Tumor Burden

2014 ◽  
Vol 31 (6) ◽  
pp. 407-414 ◽  
Author(s):  
Anneke P.J. Jilesen ◽  
Olivier R.C. Busch ◽  
Thomas M. van Gulik ◽  
Dirk J. Gouma ◽  
Els J.M. Nieveen van Dijkum
Keyword(s):  
Diagnostic Accuracy ◽  
Neuroendocrine Tumors ◽  
Chromogranin A ◽  
Tumor Burden ◽  
Pancreatic Neuroendocrine Tumors

High sensitivity of chromogranin a (CgA) as serum marker of functioning and non-functioning digestive neuroendocrine tumors

2000 ◽  
Vol 118 (4) ◽  
pp. A647
Author(s):  
Carola Severi ◽  
Stefano Angeletti ◽  
Renato Cannizzaro ◽  
Vito D. Corleto ◽  
Paola Pradella ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Chromogranin A ◽  
High Sensitivity ◽  
Serum Marker

scholarly journals On the history and some characteristics of neuroendocrine tumors of the gastrointestinal tract. Review. Part 1

2021 ◽  
pp. 60-72
Author(s):  
S. Rybakov
Keyword(s):  
Gastrointestinal Tract ◽  
Neuroendocrine Tumors ◽  
Endocrine System ◽  
Secretory Activity ◽  
Clinical Syndrome ◽  
Biologically Active ◽  
Clinical Aspects ◽  
Clinical Syndromes ◽  
Diffuse Endocrine System ◽  
Active Substances

The literature review is devoted to the analysis of numerous studies that have formed the basis for creating ideas about the diffuse endocrine system. In addition to the main endocrine glands, also there are cellular accumulations and individual cells that produce various hormones and biologically active substances. It is established that, in particular, in the organs of the gastrointestinal tract, starting from the esophagus and to the terminal parts of the large intestine, there are several types of endocrine cells with these functions. Most of them are in the pancreas, antrum of the stomach, duodenum, the initial part of the intestine, in the liver. Excessive secretory activity of these cells can cause the development of pathological clinical syndromes, characterized by the effect of the corresponding hormones. The morphological substrate of such syndromes may be tumors or diffuse hyperplasia of the corresponding cells. The author considers the pancreas as an integral part of the diffuse endocrine system, as specific endocrine functions in it perform numerous accumulations (islets of Langerhans) or individual cells. The review of the numerous neuroendocrine tumors of the gastrointestinal tract examines in detail the characteristics of some of them in historical and clinical aspects, in particular insulinoma as the most common and well-studied tumor. Glucagonoma is also considered as a neuroendocrine tumor derived from α-cells of the pancreas, is a kind of insulinoma antagonist, as it secretes an excess of the hormone glucagon, causing the development of hyperglycemic clinical syndrome in contrast to hypoglycemic, caused by insulin. It is a rare tumor and its consideration after insulinoma can be explained by the antagonistic nature of the action of hormones produced by these tumors. In the group of neuroendocrine tumors of the pancreas, glucagonoma follows the frequency of insulinoma and gastrinoma.

scholarly journals On the history and some characteristics of neuroendocrine tumors of the gastrointestinal tract. Neuroendocrine tumors of the pancreas. Part 2

2021 ◽  
pp. 70-81
Author(s):  
S. I. Rybakov
Keyword(s):  
Gastrointestinal Tract ◽  
Neuroendocrine Tumors ◽  
Endocrine System ◽  
Secretory Activity ◽  
Clinical Syndrome ◽  
Biologically Active ◽  
Clinical Aspects ◽  
Clinical Syndromes ◽  
Diffuse Endocrine System ◽  
Active Substances

The literature review presents the analysis of numerous studies that have formed the basis for creating ideas about the diffuse endocrine system,namely existence of the cellular accumulations and individual cells that produce various hormones and biologically active substances in addition to the main endocrine glands. Several types of endocrine cells with these functionshave been established, in particular, in the organs of the gastrointestinal tract, starting from the esophagus and up to the terminal parts of the large intestine. Most of them are contained in the pancreas, antrum of the stomach, duodenum, the initial part of the intestine, in the liver. Excessive secretory activity of these cells can cause the development of pathological clinical syndromes, characterized by the effects of the corresponding hormones. The tumors or diffuse hyperplasia of the corresponding cellsmay present morphological substrate of such syndromes. The author considers the pancreas as an integral part of the diffuse endocrine system, as specific endocrine functions in it perform numerous accumulations (islets of Langerhans) or individual cells. The review of the numerous neuroendocrine tumors of the gastrointestinal tract examines in detail the characteristics of some of them in historical and clinical aspects, in particular Zollinger—Ellison syndrome as the most common and well-studied tumor. Glucagonoma is also considered as a neuroendocrine tumorderived from α-cells of the pancreas, is a kind of insulinoma antagonist, as it secretes an excess of the hormone glucagon, causing the development of hyperglycemic clinical syndrome in contrast to hypoglycemic, caused by insulin. It is a rare tumor and its consideration after insulinoma can be explained by the antagonistic nature of the action of hormones produced by these tumors. In the group of neuroendocrine tumors of the pancreas, glucagonoma follows the frequency of insulinoma and gastrinoma.

Sign in / Sign up

Export Citation Format

Share Document